Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability

Verrica Pharmaceuticals (VRCA) just closed out FY 2025 with Q4 revenue of US$5.1 million and a basic EPS loss of US$0.57, alongside trailing 12 month revenue of US$35.6 million and a basic EPS loss of US$1.68. Over the past few quarters, the company has seen revenue move from US$3.4 million in Q1 2025 to US$12.7 million in Q2 and US$14.3 million in Q3, while quarterly basic EPS has ranged from a loss of US$1.03 in Q1 to a small profit of US$0.02 in Q2 and a near breakeven loss of US$0.03 in Q3. This puts the latest results in focus for how sustainable its margins really are.

See our full analysis for Verrica Pharmaceuticals.

With the headline numbers on the table, the next step is to see how this earnings print lines up with the most widely held narratives around Verrica’s growth potential and risk profile.

See what the community is saying about Verrica Pharmaceuticals

Losses Stay Elevated On US$35.6 Million In TTM Revenue

• Over the last twelve months, Verrica generated US$35.6 million in revenue but still reported net losses of US$17.9 million and trailing EPS of a US$1.68 loss.
• Consensus narrative highlights YCANTH as the main revenue engine, with pipeline programs and partnerships expected to add new revenue streams. However, the trailing net loss shows that, so far, higher sales have not been enough to offset operating costs and reliance on co pay support and milestone funding.

Forecast Growth Versus Five Year Loss Trend

• The analysis data points to forecast earnings growth of about 54.7% a year and revenue growth around 36.5% a year, while over the past five years losses have grown at roughly 10% a year.
• Bulls argue that rapid adoption of YCANTH and global rights can support strong long term revenue growth and eventually higher margins. At the same time, the history of deepening losses and the company still being unprofitable means the bullish view leans heavily on future margin improvement that is not yet visible in the recent TTM loss of US$17.9 million.
  • Bullish commentary points to potential earnings of more than US$28 million several years out, but that sits against FY 2025 quarterly swings from a small profit in Q2 2025 to an EPS loss of US$0.57 in Q4.
  • Supporters also focus on expanding addressable markets in dermatology, while the current figures show earnings volatility that makes the path from a US$1.68 TTM EPS loss to positive earnings an open execution question.

Bulls say the recent EPS volatility could be the early stage of a bigger shift in profitability, while the current loss profile keeps execution risk front and center for anyone leaning on the upside case. 🐂 Verrica Pharmaceuticals Bull Case

Cheap On P/S, But Cash Runway Is Short

• The stock trades at about 3x P/S, below the cited US pharmaceuticals average of 4.1x and peer average of 3.6x. At the same time, the data flags less than one year of cash runway and substantial shareholder dilution over the past year.
• Bears focus on the combination of funding pressure and concentration in a single key product, and the flagged short cash runway plus recent dilution support that concern. This is the case even though the lower P/S multiple and a DCF fair value of roughly US$228.70 compared with a US$6.15 share price could attract investors who are comfortable with higher financing and concentration risk.
  • Skeptical views point out that if cash runs low before operations turn sustainably profitable, further equity raises could offset any benefit from a low starting valuation for existing holders.
  • On the other hand, the gap between the DCF fair value figure and the current share price shows why some investors might still be willing to tolerate dilution and short runway risk in return for potential upside if the business delivers on growth forecasts.

Cautious investors often treat the short cash runway and history of dilution as key guardrails, even when headline valuation metrics look appealing. 🐻 Verrica Pharmaceuticals Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Verrica Pharmaceuticals on Simply Wall St. Add the company to your watchlist or portfolio so you’ll be alerted when the story evolves.

If this mix of upside and risk feels finely balanced, now is a good time to look through the numbers yourself and stress test your view. You can start with 3 key rewards and 2 important warning signs.

See What Else Is Out There

Verrica is still carrying sizeable losses, a short cash runway and dilution risk on US$35.6 million in trailing revenue, with profitability yet to settle.

If that mix of funding pressure and earnings volatility feels a bit tight for your comfort, you might want to check out 68 resilient stocks with low risk scores to quickly focus on companies where the risk profile is designed to be more resilient.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com